{"pmid":32340677,"title":"Pulmonary Pathology of Early Phase 2019 Novel Coronavirus Pneumonia.","text":["Pulmonary Pathology of Early Phase 2019 Novel Coronavirus Pneumonia.","J Thorac Oncol","Joob, Beuy","Wiwanitkit, Viroj","32340677"],"journal":"J Thorac Oncol","authors":["Joob, Beuy","Wiwanitkit, Viroj"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340677","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jtho.2020.03.013","topics":["Diagnosis"],"weight":1,"_version_":1665351883893506049,"score":8.574329,"similar":[{"pmid":32114094,"pmcid":"PMC7128866","title":"Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.","text":["Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.","There is currently a lack of pathologic data on the novel coronavirus (severe acute respiratory syndrome coronavirus 2) pneumonia, or coronavirus disease 2019 (COVID-19), from autopsy or biopsy. Two patients who recently underwent lung lobectomies for adenocarcinoma were retrospectively found to have had COVID-19 at the time of the operation. These two cases thus provide important first opportunities to study the pathology of COVID-19. Pathologic examinations revealed that apart from the tumors, the lungs of both patients exhibited edema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy inflammatory cellular infiltration, and multinucleated giant cells. Hyaline membranes were not prominent. Because both patients did not exhibit symptoms of pneumonia at the time of operation, these changes likely represent an early phase of the lung pathology of COVID-19 pneumonia.","J Thorac Oncol","Tian, Sufang","Hu, Weidong","Niu, Li","Liu, Huan","Xu, Haibo","Xiao, Shu-Yuan","32114094"],"abstract":["There is currently a lack of pathologic data on the novel coronavirus (severe acute respiratory syndrome coronavirus 2) pneumonia, or coronavirus disease 2019 (COVID-19), from autopsy or biopsy. Two patients who recently underwent lung lobectomies for adenocarcinoma were retrospectively found to have had COVID-19 at the time of the operation. These two cases thus provide important first opportunities to study the pathology of COVID-19. Pathologic examinations revealed that apart from the tumors, the lungs of both patients exhibited edema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy inflammatory cellular infiltration, and multinucleated giant cells. Hyaline membranes were not prominent. Because both patients did not exhibit symptoms of pneumonia at the time of operation, these changes likely represent an early phase of the lung pathology of COVID-19 pneumonia."],"journal":"J Thorac Oncol","authors":["Tian, Sufang","Hu, Weidong","Niu, Li","Liu, Huan","Xu, Haibo","Xiao, Shu-Yuan"],"date":"2020-03-02T11:00:00Z","year":2020,"_id":"32114094","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.jtho.2020.02.010","keywords":["covid-19 pneumonia","coronavirus","pathology","sars-cov-2"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664640875063410689,"score":55.638485},{"pmid":32294295,"title":"Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.","text":["Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.","Between February and March 2020, the Journal of Thrombosis and Hemosthasis has published four papers addressing the intricate, complex and still little understood relation between COVID-19 and thrombogenesis (1-4). ARS-Cov-2 induces in severe cases a cytokine storm that ultimately leads to the activation of the coagulation cascade, causing thrombotic phenomena (5). There is a further strong link between abnormal coagulation parameters (D-dimer and fibrin degradation products) and mortality. Tang et al. described that 71.4% of nonsurvivors and 0.6% of survivors showed evidence of disseminated intravascular coagulation (DIC), suggesting that DIC is a frequent occurrence in severe COVID-19 (4). The frequency of DIC in these patients is much higher than that reported for severe SARS (6).","J Thromb Haemost","Dolhnikoff, Marisa","Duarte-Neto, Amaro Nunes","de Almeida Monteiro, Renata Aparecida","Ferraz da Silva, Luiz Fernando","Pierre de Oliveira, Ellen","Nascimento Saldiva, Paulo Hilario","Mauad, Thais","Marcia Negri, Elnara","32294295"],"abstract":["Between February and March 2020, the Journal of Thrombosis and Hemosthasis has published four papers addressing the intricate, complex and still little understood relation between COVID-19 and thrombogenesis (1-4). ARS-Cov-2 induces in severe cases a cytokine storm that ultimately leads to the activation of the coagulation cascade, causing thrombotic phenomena (5). There is a further strong link between abnormal coagulation parameters (D-dimer and fibrin degradation products) and mortality. Tang et al. described that 71.4% of nonsurvivors and 0.6% of survivors showed evidence of disseminated intravascular coagulation (DIC), suggesting that DIC is a frequent occurrence in severe COVID-19 (4). The frequency of DIC in these patients is much higher than that reported for severe SARS (6)."],"journal":"J Thromb Haemost","authors":["Dolhnikoff, Marisa","Duarte-Neto, Amaro Nunes","de Almeida Monteiro, Renata Aparecida","Ferraz da Silva, Luiz Fernando","Pierre de Oliveira, Ellen","Nascimento Saldiva, Paulo Hilario","Mauad, Thais","Marcia Negri, Elnara"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294295","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14844","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664636192669302786,"score":40.250587}]}